Table 1.
Protocol for non-metastatic osteossarcoma* (Total time: 24 weeks)
| Weeks | Evaluations and Procedures |
|---|---|
| Initial evaluation: local and torax NMR or CT, cintigraphy, local and toraxX-ray, complete hemogram, TGO, TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation, pathology, genetics, tumor bank; BTF, U, Cr, biochemical tests (Na, K, Mg, Ca) | |
| 0 | CDDP DOXO |
| 3 | AD IFO |
| 5 | Cycle I - preoperative audiometry/ cardiac evaluation |
| 6 | CDDP DOXO |
| Orthopedics (consultation) | |
| 9 | AD IFO |
| 11 | PREOPERATIVE EVALUATION local and torax NMR or CT, cintigraphy, local and torax X-ray, complete hemogram, TGO, TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation. |
| 12 | SURGERY EVALUATION: Pathology and Genetics |
| 15 | CDDP DOXO |
| 18 | AD IFO |
| 20 | Cycle II - postoperative audiometry/ cardiac evaluation |
| 21 | CDDP DOXO |
| 24 | AD IFO |
| 27-28 | Final evaluation local and torax NMR orCT, cintigraphy, local and torax X-ray, complete hemogram, TGO, TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation. |
*
Brazilian Cooperative Group for Treatment of Bone Tumors (GBCTTO), 1999. AD: adriamycin; CDDP: cisplatin; DOXO: doxorubicin; IFO: ifosfamide.